// Archives

Spring/Summer-2009

This category contains 5 posts

Ask the Expert: What is the history behind vaccinations for Alzheimer’s disease, and how promising are they for the treatment of AD?

A potential “Alzheimer’s vaccine” has long been an interest for researchers and a hope for patients and families. The primary target for most vaccines to date has been the amyloid plaque which is found in the brains of patients with AD, and is thought by many to be the cause of the disease. The idea of using the body’s own immunity to combat amyloid buildup has great appeal…

A Cup of Coffee with Dr. Girish Nair

Dr. Girish Nair received his medical training at T.D. Medical College in Alleppey, Kerala, India. He completed his residency at the Government Medical College in Miraj, India, and then went on to gain a specialty in neurology at the Bombay Hospital Institute of Medical Sciences in Mumbai. He joined the Memory and Aging Research Center […]

Synaptic proteins and phospholipid levels increase in rat pups whose mothers were given DHA plus uridine

Congratulations to George Marzloff, one of our ADRC research coordinators, who was recently published in the January 2009 issue of Developmental Neuroscience. While pursuing his undergraduate degree, George and other researchers from the Massachusetts Institute of Technology investigated the effects of supplementing rat mothers with uridine and docosahexaenoic acid (DHA) on the brains of rat […]

Results of FDG-PET Imaging of patients with amnestic mild cognitive impairment with and without depression

The results of Dr. Mitsis’s study indicate that patients with AD and MCI with and without depression share a common decrease in relative glucose activity in the temporal and parietal lobes. These are the regions of the brain that are typically affected in AD. In contrast, in the frontal lobe of the brain, a disassociation was seen with increased activity in the AD group in regions of the frontal lobe that possibly represents compensatory activation. However, patients with MCI and depression did not show this compensatory activity but instead showed a decrease, such as that often reported in mood disorders.

Can gene therapy slow the progression of Alzheimer’s?

The Mount Sinai ADRC is excited to announce the initiation of a new nationwide study examining the effect of gene therapy on the progression of cognitive and functional decline in mild to moderate AD. Previous studies suggest that a protein called Nerve Growth Factor (NGF) can help promote the survival of acetylcholine neurons that degenerate […]